Medpace Holdings (MEDP) Other Non-Current Liabilities (2015 - 2026)
Medpace Holdings' (MEDP) quarterly Other Non-Current Liabilities came in at $59.6 million in Q2 2026, up 14.77% on a YoY basis from $51.9 million in Q2 2025, and down 0.87% quarter-over-quarter from $60.1 million in Q1 2026.
Analysis
Medpace Holdings (MEDP) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Medpace Holdings (MEDP) has reported Other Non-Current Liabilities for 12 consecutive years, with $59.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Liabilities rose 14.77% year-over-year to $59.6 million; the trailing twelve-month figure through Jun 2026 stood at $59.6 million (up 14.77% YoY), and the FY2025 full-year result was $57.7 million, up 34.92% from the prior year.
- Other Non-Current Liabilities declined to $59.6 million in Q2 2026 per MEDP's latest filing, from $60.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $60.1 million in Q1 2026 and bottomed at $17.2 million in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $35.6 million across 5 years, with a median of $29.2 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities rose 6.93% in 2022, then jumped 82.07% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $22.7 million in 2022, then climbed by 24.32% to $28.2 million in 2023, then soared by 51.43% to $42.7 million in 2024, then surged by 34.92% to $57.7 million in 2025, then grew by 3.35% to $59.6 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $59.6 million, $60.1 million, and $57.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.58 Mn |
| Mar 31, 2026 | 60.10 Mn |
| Dec 31, 2025 | 57.66 Mn |
| Sep 30, 2025 | 54.49 Mn |
| Jun 30, 2025 | 51.92 Mn |
| Mar 31, 2025 | 52.95 Mn |
| Dec 31, 2024 | 42.73 Mn |
| Sep 30, 2024 | 30.70 Mn |
| Jun 30, 2024 | 29.27 Mn |
| Mar 31, 2024 | 29.08 Mn |
| Dec 31, 2023 | 28.22 Mn |
| Sep 30, 2023 | 23.12 Mn |
| Jun 30, 2023 | 22.95 Mn |
| Mar 31, 2023 | 22.79 Mn |
| Dec 31, 2022 | 22.70 Mn |
| Sep 30, 2022 | 17.56 Mn |
| Jun 30, 2022 | 17.26 Mn |
| Mar 31, 2022 | 17.22 Mn |
| Dec 31, 2021 | 17.75 Mn |
| Sep 30, 2021 | 16.06 Mn |